APA (7th ed.) Citation

Y, H., K, M., H, I., J, T., H, U., K, N., . . . T, W. (2025). Clinical Utility of Targeted Next-Generation Sequencing for Determining Human Epidermal Growth Factor Receptor 2 Status and Optimizing Targeted Therapy in Breast Cancer. World journal of oncology, 16(4), 347. https://doi.org/10.14740/wjon2583

Chicago Style (17th ed.) Citation

Y, Hara, et al. "Clinical Utility of Targeted Next-Generation Sequencing for Determining Human Epidermal Growth Factor Receptor 2 Status and Optimizing Targeted Therapy in Breast Cancer." World Journal of Oncology 16, no. 4 (2025): 347. https://doi.org/10.14740/wjon2583.

MLA (9th ed.) Citation

Y, Hara, et al. "Clinical Utility of Targeted Next-Generation Sequencing for Determining Human Epidermal Growth Factor Receptor 2 Status and Optimizing Targeted Therapy in Breast Cancer." World Journal of Oncology, vol. 16, no. 4, 2025, p. 347, https://doi.org/10.14740/wjon2583.